Procarbazine (Matulane)

General information

Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

1969-07-22: Initial FDA approval
Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. (Based on Young et al. 1973a, Kolygin 1976, possibly others)

History of changes in EMA indication

1966-10-07: EURD

Also known as

Code names: NCI-C01810, Ro 4-6467/1
Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride
Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine

References

[insert-1] 1.0 ^1.1 Procarbazine (Matulane) package insert

[2] Procarbazine (Matulane) package insert (locally hosted backup)

[3] Procarbazine (Matulane) patient drug information (Chemocare)

[4] Procarbazine (Matulane) patient drug information (UpToDate)

[1]

[2]

[3]

[4]